Alpha Tau completes enrollment in 48-patient IMPACT pancreatic cancer Alpha DaRT pilot study

• Alpha Tau Medical completed enrollment in the IMPACT multicenter pilot study of Alpha DaRT with first-line chemotherapy for unresectable pancreatic cancer.
• Enrollment expanded from 12 to 48 treated patients, reflecting strong demand and positioning the program for a larger, pivotal trial.
• Prior early-stage studies in Israel and Canada have already been presented, supporting use as a one-time add-on with standard chemotherapy.
• IMPACT now moves into follow-up, with initial results slated for early 2027 to guide pivotal-study design.
• Management highlighted a favorable safety profile to date, aiming to keep chemotherapy dosing intact while adding local treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-095370), on August 31, 2026, and is solely responsible for the information contained therein.